Mauro Cancian
Mauro Cancian is an expert in Immunology at Azienda Ospedaliera di Padova (Italy). As of October 2026, ScienceLeadR ranks Mauro Cancian in the top 1% of experts worldwide for Angioedema, Immunologic Deficiency Syndromes and Hypersensitivity. Mauro Cancian has authored 108 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 6 of them ongoing. SLR score: 629 (community average: 125). How the SLR is computed.
LeadR Profile
Immunology
Subspecialties: Dermatology - Cardiology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1998 - 2026
Number : 108
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies. PMID 42894560 — disease management, quality of life, safety, pharmaceutical preparations, angioedemas, hereditary, therapeutics, angioedema | World Allergy Organ J | 2026 | 0 |
| Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study. PMID 42563375 — quality of life, safety, incidence, angioedemas, hereditary, aged, therapeutics, angioedema | Clin Transl Allergy | 2026 | 0 |
| Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S. PMID 42436759 — safety, angioedemas, hereditary, therapeutics, angioedema | J Allergy Clin Immunol Glob | 2026 | 0 |
| Clinical experience with berotralstat in patients with hereditary angioedema: an Italian case series from the ITACA cohort. PMID 42358134 — decision making, shared, pharmaceutical preparations, androgens, hypersensitivity, angioedemas, hereditary, therapeutics, angioedema, drug interactions, plasma | Eur Ann Allergy Clin Immunol | 2026 | 0 |
| Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials. PMID 42318595 — safety, angioedemas, hereditary, aged, therapeutics, angioedema | World Allergy Organ J | 2026 | 0 |
Clinical Studies 15
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| STOP HAE A Phase 3 Study of ADX 324 in HAE 2025-521352-38-00 — rna, small interfering, angioedemas, hereditary, prekallikrein, therapeutics, angioedema | Phase 3 | Recruiting | 2026 |
| An Open Label Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) 2023-509201-77-00 — safety, angioedemas, hereditary, therapeutics, angioedema | Phase 3 | Active not recruiting | 2022 |
| Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema 2025-522051-26-00 — safety, angioedemas, hereditary, tablets, capsules, therapeutics, angioedema | Phase 3 | Recruiting | 2026 |
| A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ CSU1) 2024-513210-36-00 — histamine antagonists, safety, urticaria, therapeutics | Phase 3 | Active not recruiting | 2025 |
| CHAPTER 4 A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents 2024-516248-24-00 — safety, angioedemas, hereditary, tablets, adolescent, therapeutics, angioedema | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map